

Supporting Information

Construction of C(sp²)–S and C(sp²)–Se Bonds via Silver(I)-Mediated Coupling Reaction of Heterocyclic Ketene Aminals with Diaryl Dichalcogenides

Xiu-Yang Jiang,^[a] Zhi-Cheng Liu,^[a] Li Fang,^[a] Sheng-Jiao Yan*^[a] and Jun Lin*^[a,b]

^a Key Laboratory of Medicinal Chemistry for Natural Resource (Yunnan University), Ministry of Education, School of Chemical Science and Technology, Yunnan University, Kunming, 650091, P. R. China.

^b State Key Laboratory of Elemento-organic Chemistry, Nankai University, Tianjin, 300071, P. R. China.

*E-mail: yansj@ynu.edu.cn or linjun@ynu.edu.cn
Fax: (+86)-871-65033215; phone: (+86)-871-65033215

Table of Contents


GeneralInformation	S2
General Procedure for the Preparation of compounds 3–5	S2
Analytic Data for the Products	S3
Crystal X-ray structure and packing diagrams of compound 3g	S21
NMR spectra of compounds 3–5	S25
References and Notes	S121

General Information

All compounds were fully characterized by spectroscopic data. The NMR spectra were recorded on a Bruker DRX500 or DRX400, chemical shifts (δ) are expressed in ppm, and J values are given in Hz, and deuterated CDCl_3 was used as solvent. The reactions were monitored by thin layer chromatography (TLC) using silica gel GF₂₅₄. The melting points were determined on XT-4A melting point apparatus and are uncorrected. HRMs were performed on a Agilent LC/Msd TOF instrument.

All chemicals and solvents were used as received without further purification unless otherwise stated. Compounds **2** were prepared according to the literature.¹


General Procedure for the Preparation of Compounds 3–5



To a 25 ml round-bottom flask, HKAs **1** (1 mmol), 1,2-diphenyldiselenane **2** (1 mmol), AgOAc (1 mmol) in dioxane (15 mL) were added. The resulting mixture was heated to reflux and stirred until all starting diphenyldiselenane was consumed, as evidenced by TLC. After cooling to room temperature, the solid AgOAc was removed by filtration. The organic layer was then concentrated under reduced pressure to yield crude product. The crude compound was then purified by recrystallization with ethyl acetate and petroleum to afford compounds **3–5** as a white solid.


Analytic Data for the Products

2-(Imidazolidin-2-ylidene)-1-phenyl-2-(phenylthio)ethanone (3a**)**




White solid, yield 94%; Mp 202–204 °C; IR (KBr): 3194, 1573, 1482, 1373, 1299, 735 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 3.53 (t, *J* = 8.8 Hz, 2H, NCH₂), 3.88 (t, *J* = 8.8 Hz, 2H, NCH₂), 5.78 (br, 1H, NH), 7.06–7.39 (m, ArH, 10H), 9.91 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 42.6, 45.8, 76.1, 124.7, 125.0, 127.4, 127.7, 129.1, 129.3, 141.0, 142.6, 168.7, 194.1; HRMS (TOF ES⁺): m/z calcd for C₁₇H₁₆N₂NaOS [(M+Na⁺)], 319.0876; found, 319.0874.

2-(Imidazolidin-2-ylidene)-1-(4-methoxyphenyl)-2-(phenylthio)ethanone (3b**)**



White solid, yield 97%; mp 176–177 °C; IR (KBr): 3366, 3269, 1576, 1369, 1241, 732 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 3.57 (t, *J* = 8.9 Hz, 2H, NCH₂), 3.75 (s, 3H, CH₃), 3.90 (t, *J* = 8.9 Hz, 2H, NCH₂), 5.72 (br, 1H, NH), 6.74 (t, *J* = 8.6 Hz, 2H, ArH), 7.06–7.26 (m, 5H, ArH), 7.45 (t, *J* = 8.6 Hz, 2H, ArH), 9.95 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 42.6, 45.8, 55.6, 75.6, 112.9, 124.6, 125.0, 129.3, 129.6, 134.9, 141.0, 160.6, 168.9, 193.2; HRMS (TOF ES⁺): m/z calcd for C₁₈H₁₈N₂NaO₂S [(M+Na⁺)], 349.0981; found, 349.0971.


2-(Imidazolidin-2-ylidene)-2-(phenylthio)-1-(*p*-tolyl)ethanone (3c**)**



White solid, yield 94%; mp 213–214 °C; IR (KBr): 3416, 3285, 1579, 1531, 1365, 1298, 744 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 2.28 (s, 3H, CH₃), 3.57 (t, *J* = 8.8 Hz, 2H, NCH₂), 3.91 (t, *J* = 8.8 Hz, 2H, NCH₂), 5.72 (br, 1H, NH), 7.02 (d, *J* = 7.8 Hz, 2H, ArH), 7.06–7.33 (m, ArH, 7H), 9.94 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 21.8, 42.6,


45.8, 75.9, 124.7, 124.9, 127.5, 128.4, 129.3, 139.1, 139.7, 141.0, 168.7, 194.1; HRMS (TOF ES⁺): m/z calcd for C₁₈H₁₈N₂NaOS [(M+Na⁺)], 333.1032; found, 333.1027.

1-(4-Fluorophenyl)-2-(imidazolidin-2-ylidene)-2-(phenylthio)ethanone (3d**)**




White solid, yield 93%; mp 182–183 °C; IR (KBr): 3305, 1580, 1532, 1370, 1303, 743 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 3.50–3.57 (m, 2H, NCH₂), 3.85–3.89 (m, 2H, NCH₂), 5.80 (br, 1H, NH), 6.84–7.41 (m, 9H, ArH), 9.86 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 42.6, 45.8, 75.9, 114.5 (d, *J* = 20.0 Hz), 124.6, 125.1, 129.4, 129.7, 138.6, 140.7, 163.4 (d, *J* = 245.0 Hz), 168.7, 192.7; HRMS (TOF ES⁺): m/z calcd for C₁₇H₁₅FN₂NaOS [(M+Na⁺)], 337.0781; found, 337.0783.

1-(4-Chlorophenyl)-2-(imidazolidin-2-ylidene)-2-(phenylthio)ethanone (3e**)**



White solid, yield 89%; mp 200–202 °C; IR (KBr): 3413, 3267, 1579, 1532, 1370, 1306, 742 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 3.56 (t, *J* = 8.9 Hz, 2H, NCH₂), 3.90 (t, *J* = 8.9 Hz, 2H, NCH₂), 5.80 (br, 1H, NH), 7.06–7.34 (m, 9H, ArH), 9.85 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 42.6, 45.8, 76.0, 124.6, 125.2, 127.9, 129.0, 129.4, 134.9, 140.6, 140.9, 168.7, 192.6; HRMS (TOF ES⁺): m/z calcd for C₁₇H₁₅ClN₂NaOS [(M+Na⁺)], 353.0486; found, 353.0486.


1-(2-Chlorophenyl)-2-(imidazolidin-2-ylidene)-2-(phenylthio)ethanone (3f**)**



White solid, yield 85%; mp 194–195 °C; IR (KBr): 3193, 1582, 1540, 1482, 1381, 1299, 747 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 3.58 (t, *J* = 8.9 Hz, 2H, NCH₂), 3.92 (t, *J* = 8.9 Hz, 2H, NCH₂), 5.80 (br, 1H, NH), 7.05–7.30 (m, 9H, ArH), 9.74 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 42.6, 45.8, 76.0, 124.6, 125.2, 127.9, 129.0, 129.4, 134.9, 140.6, 140.9, 168.7, 192.6; HRMS (TOF ES⁺): m/z calcd for C₁₇H₁₅ClN₂NaOS [(M+Na⁺)], 353.0486; found, 353.0486.


NMR (125 MHz, CDCl₃): δ = 42.5, 45.7, 125.1, 126.3, 127.6, 129.0, 129.5, 130.6, 140.2, 142.2, 168.0, 192.1; HRMS (TOF ES⁺): m/z calcd for C₁₇H₁₅ClN₂NaOS [(M+Na⁺)], 353.0486; found, 353.0485.

2-(Imidazolidin-2-ylidene)-2-((4-methoxyphenyl)selanyl)-1-phenylethanone (3g**)**




White solid, yield 94%, mp 218–220 °C; IR (KBr): 3403, 3304, 1589, 1533, 1482, 1367, 1298, 700 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 3.55 (t, *J* = 8.9 Hz, 2H, NCH₂), 3.70 (s, 3H, CH₃), 3.88 (t, *J* = 8.9 Hz, 2H, NCH₂), 5.82 (br, 1H, NH), 6.78–7.40 (m, 9H, ArH), 9.87 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 42.6, 45.8, 55.8, 115.1, 126.4, 127.1, 127.4, 127.7, 129.1, 131.6, 142.7, 157.9, 168.8, 194.1; HRMS (TOF ES⁺): m/z calcd for C₁₈H₁₉N₂O₂S [(M+H⁺)], 327.1162; found, 327.1168.

2-(Imidazolidin-2-ylidene)-1-phenyl-2-(*p*-tolylselanyl)ethanone (3h**)**




White solid, yield 95%; mp 196–197 °C; IR (KBr): 3424, 3318, 1578, 1359, 1298, 702 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 2.29 (s, 3H, ArCH₃), 3.49–3.53 (m, 2H, NCH₂), 3.85–3.88 (m, 2H, NCH₂), 5.77 (br, 1H, NH), 7.01–7.41 (m, 9H, ArH), 9.91 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 21.3, 42.6, 45.8, 76.4, 124.8, 127.4, 127.7, 129.1, 130.1, 134.7, 137.4, 142.7, 168.7, 194.0; HRMS (TOF ES⁺): m/z calcd for C₁₈H₁₉N₂OS [(M+H⁺)], 311.1213; found, 311.1216.

2-((4-Chlorophenyl)selanyl)-2-(imidazolidin-2-ylidene)-1-phenylethanone (3i**)**




White solid, yield 90%; mp 211–213 °C; IR (KBr): 3200, 1581, 1377, 1299, 705 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 3.58 (t, *J* = 8.7 Hz, 2H, NCH₂), 3.91 (t, *J* = 8.7 Hz, 2H, NCH₂), 5.73 (br, 1H, NH), 7.03–7.37 (m, 9H, ArH), 9.90 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 42.6, 45.8, 75.8, 126.0, 127.3, 127.7, 129.2, 129.3, 130.7, 139.6, 142.4, 168.6, 194.2; HRMS (TOF ES⁺): m/z calcd for C₁₇H₁₆ClN₂OS [(M+H⁺)], 331.0666; found, 331.0663.

2-((3,5-Dichlorophenyl)selanyl)-2-(imidazolidin-2-ylidene)-1-phenylethanone (3j**)**




White solid, yield 84%; mp 213–214 °C; IR (KBr): 3208, 1575, 1377, 1300, 793 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 3.55–3.61 (m, 2 H, NCH₂), 3.89–3.94 (m, 2 H, NCH₂), 5.76 (br, 1 H, NH), 6.95–7.34 (m, 8H, ArH), 9.89 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 42.6, 45.8, 74.7, 122.7, 125.2, 127.2, 127.8, 129.3, 135.8, 142.2, 145.3, 168.3, 194.1; HRMS (TOF ES⁺): m/z calcd for C₁₇H₁₅Cl₂N₂OS [(M+H⁺)], 365.0277; found, 365.0258.

2-((3-Fluorophenyl)selanyl)-2-(imidazolidin-2-ylidene)-1-phenylethanone (3k**)**




White solid, yield 88%; mp 204–205 °C; IR (KBr): 3423, 3305, 1581, 1367, 1299, 733 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 3.53 (t, *J* = 8.8 Hz, 2 H, NCH₂), 3.88 (t, *J* = 8.8 Hz, 2 H, NCH₂), 5.79 (br, 1 H, NH), 6.73–7.36 (m, 9H, ArH), 9.89 (br, 1 H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 42.6, 45.8, 75.5, 111.5 (d, *J* = 23.7Hz), 111.9 (d, *J* = 21.3 Hz), 112.0, 120.3, 127.3, 127.8, 129.2, 130.6, 144.0, 163.2 (d, *J* = 245.0Hz), 168.5, 194.1; HRMS (TOF ES⁺): m/z calcd for C₁₇H₁₆FN₂OS [(M+H⁺)], 315.0962; found, 315.0965.

2-(Imidazolidin-2-ylidene)-1-phenyl-2-(phenylselanyl)ethanone (3l**)**




White solid, yield 91%; mp 161–163 °C; IR (KBr): 3409, 3310, 1573, 1368, 1297, 728 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 3.48–3.52 (m, 2H, NCH₂), 3.86–3.90 (m, 2H, NCH₂), 5.78 (br, 1H, NH), 7.11–7.34 (m, 10H, ArH), 9.98 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 42.5, 46.0, 73.9, 125.8, 127.3, 127.5, 127.6, 128.9, 129.5, 135.7, 143.7, 168.5, 194.2; HRMS (TOF ES⁺): m/z calcd for C₁₇H₁₆N₂NaOSe [(M+Na⁺)], 367.0320; found, 367.0315.

2-(Imidazolidin-2-ylidene)-1-(4-methoxyphenyl)-2-(phenylselanyl)ethanone (**3m**)




White solid, yield 93%; mp 144–146 °C; IR (KBr): 3309, 1603, 1347, 818, 737 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 3.57–3.61 (m, 2H, NCH₂), 3.78 (s, 3H, OCH₃), 3.93–3.96 (m, 2H, NCH₂), 5.77 (br, 1H, NH), 6.75–7.43 (m, 9H, ArH), 10.04 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 42.6, 46.0, 55.6, 73.5, 112.9, 125.8, 127.4, 129.5, 129.6, 135.8, 135.9, 160.5, 168.7, 193.5; HRMS (TOF ES⁺): m/z calcd for C₁₈H₁₉N₂O₂Se [(M+H⁺)], 375.0606; found, 375.0601.

2-(Imidazolidin-2-ylidene)-2-(phenylselanyl)-1-(*p*-tolyl)ethanone (**3n**)




White solid, yield 91%; mp: 205–207 °C; IR (KBr): 3391, 3252, 1572, 1529, 1366, 1300, 733 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 2.12 (s, ArCH₃), 3.55–3.66 (m, 2H, NCH₂), 3.88–3.95 (m, 2H, NCH₂), 5.74 (br, 1H, NH), 6.74 (d, *J* = 8.6 Hz, 2H, ArH), 7.12–7.27 (m, 5H, ArH), 7.39 (d, *J* = 8.6 Hz, 2H, ArH), 10.02 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 42.6, 46.0, 55.6, 67.5, 112.8, 125.8, 127.4, 129.5, 129.6, 135.8, 135.9, 160.5, 168.7, 193.5; HRMS (TOF ES⁺): m/z calcd for C₁₈H₁₉Na₂OSe [(M+H⁺)], 359.0657; found, 359.0661.

1-(4-Fluorophenyl)-2-(imidazolidin-2-ylidene)-2-(phenylselanyl)ethanone (**3o**)




White solid, yield 87%; mp 167–169 °C; IR (KBr): 3412, 3312, 1575, 1525, 1367, 1298, 726 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 3.53–3.58 (m, 2H, NCH₂), 3.90–3.94 (m, 2H, NCH₂), 5.81 (br, 1H, NH), 6.85–6.90 (m, 2H, ArH), 7.14–7.15 (m, 1H, ArH), 7.22–7.37 (m, 6H, ArH), 9.96 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 42.5, 46.0, 73.7, 114.5 (d, *J* = 20.0 Hz), 126.0, 127.4, 129.6, 129.6, 135.5, 139.6, 163.2 (d, *J* = 246.3 Hz), 168.6, 192.9; HRMS (TOF ES⁺): m/z calcd for C₁₇H₁₆FN₂OSe [(M+H⁺)], 363.0406; found, 363.0412.

1-(4-Chlorophenyl)-2-(imidazolidin-2-ylidene)-2-(phenylselanyl)ethanone (**3p**)




White solid, yield 88%; mp 184–186 °C; IR (KBr): 3405, 3263, 1576, 1528, 1369, 1305, 736 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 3.56–3.60 (m, 2H, NCH₂), 3.91–3.96 (m, 2H, NCH₂), 5.77 (br, 1H, NH), 7.13–7.28 (m, 9H, ArH), 9.95 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 42.5, 46.0, 73.7, 126.0, 127.3, 127.8, 128.9, 129.6, 134.7, 135.4, 141.9, 168.6, 192.8; HRMS (TOF ES⁺): m/z calcd for C₁₇H₁₆ClN₂OSe [(M+H⁺)], 379.0111; found, 379.0103.

2-(nitro(phenylthio)methylene)imidazolidine (**3q**)




White solid, yield 88%; mp 163.5–164 °C; IR (KBr): 3350, 3256, 1576, 1392, 1335, 738 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 3.75–3.79 (m, 2H, NCH₂), 3.95–4.00 (m, 2H, NCH₂), 5.83 (br, 1H, NH), 7.13–7.17 (m, 3H, ArH), 7.24–7.28 (m, 2H, ArH), 8.83(br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 43.1, 45.6, 98.4, 125.6, 125.9, 129.1, 136.1, 163.3; HRMS (TOF ES⁺): m/z calcd for C₁₀H₁₁N₃NaO₂S [(M+Na⁺)], 260.0464; found, 260.0462.

1-Phenyl-2-(phenylthio)-2-(tetrahydropyrimdin-2(1*H*)-ylidene)ethanone (4a**)**




White solid, yield 95%; mp 167–1689 °C; IR (KBr): 3352, 3279, 1586, 1344, 1205, 742 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 1.79–1.82 (m, 2H, NCH₂), 3.27–3.43 (m, 4H, NCH₂), 6.49 (br, 1H, NH), 7.04–7.08 (m, 3H, ArH), 7.15–7.18 (m, 4H, ArH), 7.24–7.28 (m, 2H, ArH); ¹³C NMR (125 MHz, CDCl₃): δ = 20.4, 38.8, 39.5, 78.4, 124.7, 125.0, 126.8, 127.7, 128.5, 129.2, 141.0, 143.9, 160.8, 193.0; HRMS (TOF ES⁺): m/z calcd for C₁₈H₁₉N₂OS [(M+H⁺)], 311.1213; found, 211.1209.

1-(4-Methoxyphenyl)-2-(phenylthio)-2-(tetrahydropyrimidin-2(1*H*)-ylidene)ethanone (4b**)**



White solid, yield 98%; mp 177–178 °C; IR (KBr): 3364, 3050, 1585, 1344, 1241, 735 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 1.93–1.96 (m, 2H, CH₂), 3.30–3.35 (m, 2H, NCH₂), 3.43–3.49 (m, 2H, NCH₂), 3.74 (s, 3H, OCH₃), 6.49 (br, 1H, NH), 6.71 (d, J = 7.3 Hz, 2H, ArH), 7.08–7.26 (m, 5H, ArH), 7.33 (d, J = 7.3 Hz, 2H, ArH), 12.05 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 20.4, 38.8, 39.5, 55.5, 112.9, 124.6, 125.0, 128.9, 129.3, 136.3, 141.1, 160.0, 160.9, 192.4; HRMS (TOF ES⁺): m/z calcd for C₁₉H₂₁N₂O₂S [(M+H⁺)], 341.1318; found, 341.1316.


2-(Phenylthio)-2-(tetrahydropyrimidin-2(1*H*)-ylidene)-1-(*p*-tolyl)ethanone (4c**)**



White solid, yield 96%; mp 175–177 °C; IR (KBr): 3330, 3052, 1584, 1339, 1164, 746 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 1.88–1.92 (m, 2H, NCH₂), 2.26 (s, 3H, ArCH₃), 3.25–3.29 (m, 2H, NCH₂), 3.40–3.47 (m, 2H, NCH₂), 6.48 (br, 1H, NH), 6.98 (d, J = 7.6 Hz, 2H, ArH), 6.97–7.12 (m, 3H, ArH), 7.22–7.25 (m, 4H, ArH); ¹³C NMR (125 MHz, CDCl₃): δ = 20.4, 21.8, 38.8, 39.5, 78.2, 124.6, 125.0, 127.0, 128.3, 129.2, 138.3, 141.1,


160.8, 193.0; HRMS (TOF ES⁺): m/z calcd for C₁₉H₂₁N₂OS, [(M+H⁺)], 325.1369; found, 325.1365.

1-(4-Fluorophenyl)-2-(phenylthio)-2-(tetrahydropyrimidin-2(1*H*)-ylidene)ethanone (4d**)**




White solid, yield 92%; mp 122–124 °C; IR (KBr): 3322, 3060, 1586, 1343, 1210, 746 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ = 1.93–1.99 (m, 2H, CH₂), 3.39–3.43 (m, 4H, NCH₂), 6.51 (br, 1H, NH), 6.83–7.32 (m, 9H, ArH), 11.92 (br, 1H, NH); ¹³C NMR (100 MHz, CDCl₃): δ = 20.0, 39.0, 39.0, 77.9, 114.1 (d, *J* = 26.3 Hz), 124.2, 124.7, 128.6 (d, *J* = 8.0 Hz), 128.9, 139.4, 140.3, 160.4, 162.5 (d, *J* = 245.0 Hz), 191.3; HRMS (TOF ES⁺): m/z calcd for C₁₈H₁₇FN₂NaOS [(M+Na⁺)], 351.0938; found, 351.0637.

1-(4-Chlorophenyl)-2-(phenylthio)-2-(tetrahydropyrimidin-2(1*H*)-ylidene)ethanone (4e**)**



White solid, yield 90%; mp 180–181 °C; IR (KBr): 330, 3052, 1584, 1339, 1164, 746 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 1.95–1.98 (m, 2H, CH₂), 3.39–3.44 (m, 4H, NCH₂), 6.52 (br, 1H, NH), 7.07–7.48 (m, 9H, ArH), 11.85 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 20.4, 39.1, 39.1, 78.5, 124.6, 125.2, 127.9, 128.5, 129.3, 134.2, 140.6, 142.2, 160.8, 191.6; HRMS (TOF ES⁺): m/z calcd for C₁₈H₁₇ClN₂NaOS [(M+Na⁺)], 367.0642; found, 367.0637.


1-(2-Chlorophenyl)-2-(phenylthio)-2-(tetrahydropyrimidin-2(1*H*)-ylidene)ethanone (4f**)**



White solid, yield 87%; mp 163–165 °C; IR (KBr): 3261, 1593, 1341, 1210, 747 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ = 1.95–1.99 (m, 2H, CH₂), 3.38–3.44 (m, 4H, NCH₂), 7.00–7.28 (m, 9H, ArH); ¹³C NMR (100 MHz, CDCl₃): δ = 19.9, 38.7, 38.7, 79.5, 124.5,


124.7, 125.9, 126.9, 128.4, 128.6, 129.1, 130.1, 139.7, 142.4, 160.0, 189.9; HRMS (TOF ES⁺): m/z calcd for C₁₈H₁₇ClN₂NaOS [(M+Na⁺)], 367.0642; found, 367.0635.

2-((4-Methoxyphenyl)selanyl)-1-phenyl-2-(tetrahydropyrimidin-2(1*H*)-ylidene)ethanone (**4g**)




White solid, yield 95%; mp 174–176 °C; IR (KBr): 3368, 3187, 1592, 1354, 1232, 743 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ = 1.93–1.96 (m, 2H, CH₂), 3.35–3.45 (m, 4H, NCH₂), 3.76 (s, 3H, OCH₃), 6.56 (br, 1H, NH), 6.78–7.31 (m, 9H, ArH), 11.93 (br, 1H, NH); ¹³C NMR (100 MHz, CDCl₃): δ = 20.1, 38.9, 38.9, 55.5, 79.2, 114.7, 125.8, 126.6, 127.3, 128.1, 131.4, 143.6, 157.5, 160.5, 192.6; HRMS (TOF ES⁺): m/z calcd for C₁₉H₂₁N₂O₂S [(M+H⁺)], 341.1318; found, 341.1319.

1-Phenyl-2-(tetrahydropyrimidin-2(1*H*)-ylidene)-2-(*p*-tolylselanyl)ethanone (**4h**)




White solid, yield 96%; mp 213–214 °C; IR (KBr): 3369, 1593, 1342, 1208, 800 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 1.94–1.97 (m, 2H, CH₂), 2.29 (s, 3H, ArCH₃), 3.31–3.34 (m, 2H, NCH₂), 3.45–3.49 (m, 2H, NCH₂), 6.51 (br, 1H, NH), 6.99–7.32 (m, 9H, ArH), 11.97 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 20.4, 21.3, 38.8, 39.5, 78.7, 124.7, 126.9, 127.6, 128.4, 130.0, 134.7, 137.4, 143.9, 160.8, 193.0; HRMS (TOF ES⁺): m/z calcd for C₁₉H₂₁N₂OS [(M+H⁺)], 325.1369; found, 325.1364.

2-((4-Chlorophenyl)selanyl)-1-phenyl-2-(tetrahydropyrimidin-2(1*H*)-ylidene)ethanone (**4i**)




White solid, yield 93%; mp 210–211 °C; IR (KBr): 3360, 1588, 1344, 1210, 809 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 1.93–1.96 (m, 2H, CH₂), 3.33–3.36 (m, 2H, NCH₂), 3.44–3.47 (m, 2H, NCH₂), 6.43 (br, 1H, NH), 7.00–7.27 (m, 9H, ArH), 11.89 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 20.4, 38.8, 39.5, 78.1, 125.9, 126.7, 127.7, 128.6, 129.3, 130.7, 139.6, 143.7, 160.7, 193.1; HRMS (TOF ES⁺): m/z calcd for C₁₈H₁₈ClN₂OS [(M+H⁺)], 345.0823, found, 345.0829.

2-((3,5-Dichlorophenyl)selanyl)-1-phenyl-2-(tetrahydropyrimidin-2(1H)-ylidene)ethanone (4j)



White solid, yield 85%; mp 223–225 °C; IR (KBr): 3276, 3067, 1596, 1334, 1214, 786 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 1.96–2.01 (m, 2H, CH₂), 3.34–3.38 (m, 2H, NCH₂), 3.46–3.50 (m, 2H, NCH₂), 6.35 (br, 1H, NH), 6.94–7.27 (m, 8H, ArH), 11.89 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 20.3, 38.8, 39.6, 122.7, 125.2, 126.7, 127.8, 128.7, 135.8, 143.5, 145.3, 160.5, 193.4; HRMS (TOF ES⁺): m/z calcd for C₁₈H₁₇Cl₂N₂OS [(M+H⁺)], 379.0433; found, 379.0437.


2-((4-Fluorophenyl)selanyl)-1-phenyl-2-(tetrahydropyrimidin-2(1H)-ylidene)ethanone (4k)



White solid, yield 92%; mp 181–183 °C; IR (KBr): 3283, 1590, 1342, 1210, 780 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 1.95–1.98 (m, 2H, CH₂), 3.32–3.36 (m, 2H, NCH₂), 3.67–3.72 (m, 2H, NCH₂), 6.43 (br, 1H, NH), 6.73–7.29 (m, 9H, ArH), 11.93 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 20.4, 38.8, 39.5, 111.5 (d, J = 23.8 Hz), 112.0 (d,


$J = 21.3$ Hz), 120.3, 123.1, 126.8, 127.7, 128.6, 130.5, 143.9, 160.7, 163.6 (d, $J = 246.3$ Hz), 164.8, 193.2; HRMS (TOF ES $^+$): m/z calcd for C₁₈H₁₈FN₂OS [(M+H $^+$)], 329.1118; found, 329.1118.

1-Phenyl-2-(phenylselanyl)-2-(tetrahydropyrimidin-2(1*H*)-ylidene)ethanone (**4l**)




White solid, yield 92%; mp 162–164 °C; IR (KBr): 3353, 1587, 1343, 741 cm $^{-1}$; 1 H NMR (500 MHz, CDCl $_3$): δ = 1.94–1.98 (m, 2H, CH $_2$), 3.32–3.37 (m, 2H, NCH $_2$), 3.46–3.50 (m, 2H, NCH $_2$), 6.57 (br, 1 H, NH), 7.15–7.31 (m, 10H, ArH), 12.12 (br, 1H, NH); 13 C NMR (125 MHz, CDCl $_3$): δ = 20.0, 38.5, 39.2, 77.8, 125.3, 126.3, 126.8, 127.1, 127.7, 129.0, 135.3, 144.6, 160.1, 192.6; HRMS (TOF ES $^+$): m/z calcd for C₁₈H₁₉N₂OSe [(M+H $^+$)], 359.0657, found, 359.0668.

1-(4-Methoxyphenyl)-2-(phenylselanyl)-2-(tetrahydropyrimidin-2(1*H*)-ylidene)ethanone (**4m**)




White solid, yield 95%; mp 154–156 °C; IR (KBr): 3353, 1581, 1344, 1240, 799 cm $^{-1}$; 1 H NMR (500 MHz, CDCl $_3$): δ = 1.90–1.95 (m, 2H, CH $_2$), 3.33–3.45 (m, 4H, NCH $_2$), 3.73 (s, 3H, OCH $_3$), 6.53 (br, 1H, NH), 6.69–7.29 (m, 9H, ArH); 13 C NMR (125 MHz, CDCl $_3$): δ = 20.5, 39.2, 39.8, 55.5, 112.8, 125.8, 127.3, 128.8, 129.5, 135.9, 137.6, 159.9, 160.8, 192.5; HRMS (TOF ES $^+$): m/z calcd for C₁₉H₂₁N₂O₂Se [(M+H $^+$)], 389.0763; found, 389.0768.

2-(Phenylselanyl)-2-(tetrahydropyrimidin-2(1*H*)-ylidene)-1-(*p*-tolyl)ethanone (**4n**)




White solid, yield 94%; mp 157–159 °C; IR (KBr): 3363, 3325, 1582, 1341, 1207, 742 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 1.94–1.97 (m, 2H, CH₂), 2.31 (s, 3H, ArCH₃), 3.34–3.47 (m, 4H, NCH₂), 6.56 (br, 1H, NH), 7.01–7.30 (m, 9H, ArH), 12.17 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 20.5, 21.8, 39.0, 39.7, 78.1, 125.8, 126.9, 127.3, 128.3, 129.5, 135.9, 138.0, 142.2, 160.7, 193.2; HRMS (TOF ES⁺): m/z calcd for C₁₉H₂₁N₂OSe [(M+H⁺)], 373.0814; found, 373.0817.

1-(4-Fluorophenyl)-2-(phenylselanyl)-2-(tetrahydropyrimidin-2(1*H*)-ylidene)ethanone (**4o**)




White solid, yield 90%; mp 139–140 °C; IR (KBr): 3322, 1582, 1346, 1210, 740 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 1.93–1.98 (m, 2H, CH₂), 3.40–3.47 (m, 4H, NCH₂), 6.59 (br, 1H, NH), 6.85–7.30 (m, 9H, ArH), 12.07 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 20.4, 39.6, 40.9, 78.5, 114.4 (d, *J* = 21.3 Hz), 125.9, 127.2, 128.9, 129.6, 135.6, 141.1, 160.7, 163.8, 191.8; HRMS (TOF ES⁺): m/z calcd for C₁₈H₁₈FN₂OSe [(M+H⁺)], 377.0563; found, 377.0565.

1-(4-Chlorophenyl)-2-(phenylselanyl)-2-(tetrahydropyrimidin-2(1*H*)-ylidene)ethanone (**4p**)




White solid, yield 86%; mp 176–177 °C; IR (KBr): 3319, 3057, 1581, 1345, 1205, 740 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 1.91–1.94 (m, 2H, CH₂), 3.36–3.41 (m, 4H, NCH₂), 6.58 (br, 1H, NH), 7.12–7.25 (m, 9H, ArH), 11.98 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 20.4, 39.4, 39.4, 78.3, 126.0, 127.2, 127.8, 128.4, 129.6, 133.9, 135.5, 143.4, 160.6, 191.6; HRMS (TOF ES⁺): m/z calcd for C₁₈H₁₈ClN₂OSe [(M+H⁺)], 393.0265; found, 393.0267.

1-(2-Chlorophenyl)-2-(imidazolidin-2-ylidene)-2-(phenylselanyl)ethanone (**4q**)




White solid, yield 83%; mp 151–153 °C; IR (KBr): 3350, 1589, 1350, 1211, 747 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 1.89–1.93 (m, 2H, CH₂), 3.28–3.32 (m, 2H, NCH₂), 3.41–3.45 (m, 2H, NCH₂), 6.49 (br, 1H, NH), 6.99–7.24 (m, 9H, ArH), 11.78 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 20.4, 39.0, 39.6, 79.8, 125.9, 126.4, 127.7, 128.7, 129.4, 130.5, 134.9, 144.0, 160.2, 190.1; HRMS (TOF ES⁺): m/z calcd for C₁₈H₁₇ClN₂NaOSe [(M+Na⁺)], 415.0087, found, 415.0083.

2-(nitro(phenylthio)methylene)hexahydropyrimidine (**4r**)




White solid, yield 90%; mp 152.5–153 °C; IR (KBr): 3284, 1585, 1356, 1200, 1127, 738 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 1.93–1.98 (m, 2H, CH₂), 3.42–3.47 (m, 4H, NCH₂), 7.11–7.15 (m, 3H, ArH), 7.22–7.26 (m, 2H, ArH); ¹³C NMR (125 MHz, CDCl₃): δ = 19.0, 39.0, 39.0, 100.8, 125.5, 125.9, 129.1, 135.7, 155.7; HRMS (TOF ES⁺): m/z calcd for C₁₁H₁₃N₃NaO₂S [(M+Na⁺)], 274.0621; found, 274.0619.

2-(1,3-Diazepan-2-ylidene)-1-phenyl-2-(phenylthio)ethanone (**5a**)




White solid, yield 92%; mp 177–178 °C; IR (KBr): 3363, 1594, 1343, 1202, 742 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 1.75–1.81 (m, 4H, CH₂CH₂), 3.20–3.23 (m, 2H, NCH₂), 3.45–3.48 (m, 2H, NCH₂), 6.55 (br, 1H, NH), 7.08–7.31 (m, 10H, ArH), 12.14 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 28.0, 28.3, 45.5, 46.3, 81.6, 124.8, 125.1, 126.9, 127.6, 128.7, 129.3, 140.9, 143.9, 170.7, 194.2; HRMS (TOF ES⁺): m/z calcd for C₁₉H₂₁N₂OS [(M+H⁺)], 325.1369; found, 325.1368.

2-(1,3-Diazepan-2-ylidene)-2-(phenylselanyl)-1-(*p*-tolyl)ethanone (**5b**)




White solid, yield 93%; mp 157–158 °C; IR (KBr): 3317, 2932, 1605, 1349, 1200, 741 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 1.73–1.80 (m, 4H, CH₂CH₂), 2.29 (s, 3H, ArCH₃), 3.18–3.20 (m, 2H, NCH₂), 3.43–3.47 (m, 2H, NCH₂), 6.54 (br, 1H, NH), 7.01 (d, *J* = 7.7 Hz, 2H), 7.00–7.13 (m, 3H, ArH), 7.24–7.27 (m, 3H, ArH), 12.20 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 21.8, 28.1, 28.3, 45.5, 46.3, 81.4, 124.8, 125.1, 127.1, 128.3, 128.3, 129.3, 138.6, 141.0, 170.8, 194.2; HRMS (TOF ES⁺): m/z calcd for C₂₀H₂₃N₂OS [(M+H⁺)], 339.1526, found, 339.1518.

2-(1,3-Diazepan-2-ylidene)-1-(4-fluorophenyl)-2-(phenylthio)ethanone (**5c**)



White solid, yield 90%; mp 124–125 °C; IR (KBr): 3331, 3060, 1591, 1348, 1207, 847, 740 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 1.76–1.84 (m, 4H, CH₂CH₂), 3.22–3.26 (m, 2H, NCH₂), 3.46–3.50 (m, 2H, NCH₂), 6.59 (br, 1H, NH), 6.85–6.91 (m, 2H, ArH), 7.09–7.14 (m, 3H, ArH), 7.25–7.29 (m, ArH, 2H), 7.33–7.36 (m, ArH, 2H), 12.12 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 28.0, 28.2, 45.5, 46.3, 81.5, 114.4 (d, *J* = 21.3 Hz), 124.7, 125.2, 129.2, 129.4, 139.9, 140.6, 163.0 (d, *J* = 245.0 Hz), 170.7, 192.80; HRMS (TOF ES⁺): m/z calcd for C₁₉H₁₉FN₂NaOS [(M+Na⁺)], 365.1094; found, 365.1087.


1-(4-Chlorophenyl)-2-(1,3-diazepan-2-ylidene)-2-(phenylthio)ethanone (**5d**)



White solid, yield 87%; mp 156–157 °C; IR (KBr): 3325, 3053, 1594, 1349, 1202, 833, 744 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 1.68–1.81 (m, 4H, CH₂CH₂), 3.20–3.3.24 (m, 2H, NCH₂), 3.67–3.70 (m, 2H, NCH₂), 6.56 (br, 1H, NH), 7.05–7.25 (m, 9H, ArH), 12.06 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 27.9, 28.2, 45.5, 46.3, 81.5, 124.7, 125.3,


127.8, 128.5, 129.4, 134.4, 140.5, 142.2, 170.6, 192.7; HRMS (TOF ES⁺): m/z calcd for C₁₉H₂₀ClN₂OS [(M+H⁺)], 359.0979; found, 359.0975.

2-(1,3-Diazepan-2-ylidene)-2-((4-methoxyphenyl)thio)-1-phenylethanone (5e**)**




White solid, yield 96%; mp 171–172 °C; IR (KBr): 3316, 2930, 1600, 1342, 1238, 816 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 1.75–1.79 (m, 4H, CH₂CH₂), 3.19–3.23 (m, 2H, NCH₂), 3.42–3.47 (m, 2H, NCH₂), 3.76 (s, 3H, OCH₃), 6.64 (br, 1H, NH), 6.80 (d, J = 8.5 Hz), 6.98 (d, J = 8.5 Hz), 7.18–7.26 (m, 3H, ArH), 7.28–7.32 (m, 2H, ArH), 12.11 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 28.0, 28.3, 45.5, 46.3, 55.8, 82.8, 115.1, 126.3, 126.9, 127.6, 128.6, 131.5, 144.0, 157.9, 170.8, 194.1; HRMS (TOF ES⁺): m/z calcd for C₂₀H₂₃N₂O₂S [(M+H⁺)], 355.1475; found, 355.147.

2-(1,3-Diazepan-2-ylidene)-1-phenyl-2-(*p*-tolylthio)ethanone (5f**)**




White solid, yield 95%; mp 175–177 °C; IR (KBr): 3334, 3046, 1600, 1345, 1200, 800 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 1.75–1.81 (m, 4H, CH₂CH₂), 2.30 (s, 3H, ArCH₃), 3.19–3.23 (m, 2H, NCH₂), 3.42–3.48 (m, 2H, NCH₂), 6.58 (br, 1H, NH), 6.98 (d, J = 8.2 Hz, 2H, ArH), 7.06 (d, J = 8.2 Hz, 2H, ArH), 7.17–7.32 (m, 5H, ArH), 12.14(br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 21.3, 28.0, 28.3, 45.5, 46.3, 81.9, 124.8, 126.9, 127.6, 128.6, 130.1, 134.8, 137.2, 143.9, 170.7, 194.1; HRMS (TOF ES⁺): m/z calcd for C₂₀H₂₃N₂OS [(M+H⁺)], 339.1526; found, 339.1527.

2-((4-Chlorophenyl)thio)-2-(1,3-diazepan-2-ylidene)-1-phenylethanone (5g**)**




White solid, yield 91%; mp 200–202 °C; IR (KBr): 3318, 1603, 1346, 1199, 803 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 1.74–182 (m, 4H, CH₂CH₂), 3.21–3.23 (m, 2H, NCH₂), 3.45–3.48 (m, 2H, NCH₂), 6.48 (br, 1H, NH), 7.00 (d, *J* = 8.6 Hz, 2H, ArH), 7.17 –7.28 (m, 7H, ArH), 12.1 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 27.9, 28.2, 45.5, 46.3, 81.2, 126.0, 126.7, 127.7, 128.8, 129.4, 130.8, 139.5, 143.7, 170.5, 194.2; HRMS (TOF ES⁺): m/z calcd for C₁₉H₂₀ClN₂OS [(M+H⁺)], 359.0979; found, 359.0982.

2-(1,3-Diazepan-2-ylidene)-2-((3,5-dichlorophenyl)thio)-1-phenylethanone (5h**)**




White solid, yield 83%; mp 139–141 °C; IR (KBr): 3308, 1561, 1348, 1206, 791 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 1.79–1.84 (m, 4H, CH₂CH₂), 3.24–3.28 (m, 2H, NCH₂), 3.47–3.50 (m, 2H, NCH₂), 6.38 (br, 1H, NH), 6.91 (s, 2H, ArH), 7.04 (s, 1H, ArH), 7.20–7.27 (m, 5H, ArH), 12.07 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 27.8, 28.1, 45.4, 46.3, 80.0, 122.7, 125.3, 126.6, 127.8, 128.9, 135.8, 143.5, 145.1, 170.1, 194.3; HRMS (TOF ES⁺): m/z calcd for C₁₉H₁₉Cl₂N₂OS [(M+H⁺)], 393.0590; found, 393.0596.

2-(1,3-Diazepan-2-ylidene)-2-((4-fluorophenyl)thio)-1-phenylethanone (5i**)**




White solid, yield 88%, mp 188–189 °C; IR (KBr): 3255, 1556, 1354, 1210, 776 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 1.75–1.83 (m, 4H, CH₂CH₂), 3.19–3.23 (m, 2H, NCH₂), 3.42–3.47 (m, 2H, NCH₂), 6.48 (br, 1H, NH), 6.74–6.86 (m, 3H, ArH), 7.15–7.83 (m, 6H, ArH), 12.09 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 27.9, 28.2, 45.5, 46.3, 111.5 (d, *J* = 23.8 Hz), 112.0 (d, *J* = 21.3 Hz), 120.4, 126.8, 127.3, 127.7, 128.7, 128.8, 130.6, 143.7, 163.8 (d, *J* = 246.3 Hz), 170.4, 194.2; HRMS (TOF ES⁺): m/z calcd for C₁₉H₂₀FN₂OS [(M+H⁺)], 343.1275; found, 343.1271.

2-(1,3-Diazepan-2-ylidene)1-phenyl-2-(phenylselanyl)ethanone (5j**)**




White solid, yield 90%; mp 154–156 °C; IR (KBr): 3347, 1593, 1342, 1202, 737 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 1.72–1.77 (m, 4H, CH₂CH₂), 3.15–3.19 (m, 2H, CH₂), 3.42–3.46 (m, 2H, CH₂), 6.53 (br, 1H, NH), 7.12–7.28 (m, 10H, ArH), 12.17 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 28.2, 28.2, 45.7, 46.4, 81.6, 125.9, 126.8, 127.5, 127.6, 128.5, 129.5, 135.7, 145.0, 170.7, 194.4; HRMS (TOF ES⁺): m/z calcd for C₁₉H₂₁N₂OSe [(M+H⁺)], 373.0814; found, 373.0816.

2-(1,3-Diazepan-2-ylidene)-2-(phenylselanyl)-1-(p-tolyl)ethanone (**5k**)



White solid, yield 93%, mp 125–127 °C; IR (KBr): 3308, 1603, 1346, 1204, 818, 736 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 1.72–1.77 (m, 4H, CH₂CH₂), 3.15–3.18 (m, 2H, NCH₂), 3.41–3.45 (m, 2H, NCH₂), 6.50 (br, 1H, NH), 7.00 (d, *J* = 7.4 Hz, 2H, ArH), 7.13–7.26 (m, 7H, ArH), 12.19 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 21.8, 28.1, 28.2, 45.7, 46.5, 81.5, 125.9, 127.0, 127.4, 128.3, 129.5, 135.8, 138.5, 142.1, 170.8, 194.5; HRMS (TOF ES⁺): m/z calcd for C₂₀H₂₃N₂OSe [(M+H⁺)], 387.0970; found, 387.0970.


2-(1,3-Diazepan-2-ylidene)-1-(4-fluorophenyl)-2-(phenylselanyl)ethanone (**5l**)



White solid, yield 86%; mp 137–138 °C; IR (KBr): 3319, 3053, 1598, 1349, 1207, 841, 737 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 1.73–1.80 (m, 4H, CH₂CH₂), 2.17 (s, 3H, ArH), 3.18–3.22 (m, 2H, NCH₂), 3.43–3.48 (m, 2H, NCH₂), 6.54 (br, 1H, NH), 6.86 (t, *J* = 8.5 Hz, 2H, ArH), 7.17–7.30 (m, 7H, ArH), 12.14 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ = 28.0, 28.2, 45.6, 46.5, 81.5, 114.4 (d, *J* = 21.3 Hz), 126.0, 127.4, 129.0,

129.6, 135.5, 141.0, 163.0 (d, $J = 245.0$ Hz), 170.7, 193.1; HRMS (TOF ES $^+$): m/z calcd for C₁₉H₂₀FN₂Ose [(M+H $^+$)], 391.0719; found, 391.0718.

1-(4-Chlorophenyl)-2-(1,3-diazepan-2-ylidene)-2-(phenylselanyl)ethanone (**5m**)



White solid, yield 85%; mp 141–143 °C; IR (KBr): 3315, 3064, 1590, 1346, 1203, 739 cm $^{-1}$; 1 H NMR (500 MHz, CDCl $_3$): δ = 1.77–1.83 (m, 4H, CH₂CH₂), 3.22–3.25 (m, 2H, NCH₂), 3.46–3.50 (m, 2H, NCH₂), 6.58 (br, 1H, NH), 7.14–7.33 (m, 9H, ArH), 12.15 (br, 1H, NH); 13 C NMR (125 MHz, CDCl $_3$): δ = 28.0, 28.0, 45.6, 46.4, 81.5, 126.1, 127.4, 127.8, 128.4, 129.6, 134.3, 135.4, 143.4, 170.6, 192.9; HRMS (TOF ES $^+$): m/z calcd for C₁₉H₂₀ClN₂OSe [(M+H $^+$)], 407.0424; found, 407.0416.

Crystal X-ray structure and packing diagrams of compound 3g²




Fig. A ORTEP view of the molecular structure of 3g, thermal ellipsoids are drawn at 30% probability.




Fig. B Packing in the crystal structure of 3g, viewed along the *b* axis.




Fig. C Packing in the crystal structure of 3g, viewed along the *a* axis.

Table S1. Crystal data and structure refinement for **3g**

Empirical formula	C ₁₈ H ₁₈ N ₂ O ₂ S		
Formula weight	326.40		
Temperature	298(2) K		
Wavelength	0.71073 Å		
Crystal system, space group	Monoclinic, P2(1)/c		
Unit cell dimensions	a = 11.5631(18) Å	alpha = 90 deg.	b = 15.924(3) Å
	c = 8.8842(14) Å	beta = 102.048(2) deg.	gamma = 90 deg.
Volume	1599.8(4) Å ³		
Z, Calculated density	4, 1.355 Mg/m ³		
Absorption coefficient	0.214 mm ⁻¹		
F(000)	688		
Crystal size	0.23 x 0.16 x 0.14 mm		
Theta range for data collection	1.80 to 28.19 deg.		
Limiting indices	-15<=h<=15, -20<=k<=20, -8<=l<=11		
Reflections collected / unique	10822 / 3761 [R(int) = 0.0468]		
Completeness to theta = 28.19	95.5 %		
Absorption correction	Semi-empirical from equivalents		
Max. and min. transmission	0.9707 and 0.9525		
Refinement method	Full-matrix least-squares on F ²		
Data / restraints / parameters	3761 / 0 / 209		
Goodness-of-fit on F ²	0.926		
Final R indices [I>2sigma(I)]	R1 = 0.0476, wR2 = 0.1024		
R indices (all data)	R1 = 0.0963, wR2 = 0.1267		
Largest diff. peak and hole	0.178 and -0.268 e.Å ⁻³		

Table S2. Geometric parameters of compound **3g**

<i>Bond lengths</i> (Å)			
N(1)-C(9)	1.314(3)	C(6)-H(6)	0.9300
N(1)-C(11)	1.457(3)	C(7)-H(7)	0.9300
N(1)-H(1)	0.8600	C(8)-C(12)	1.409(3)
N(2)-C(9)	1.334(3)	C(8)-C(9)	1.413(3)
N(2)-C(10)	1.459(3)	C(10)-C(11)	1.509(3)
N(2)-H(2)	0.8600	C(10)-H(10A)	0.9700
O(1)-C(2)	1.378(3)	C(10)-H(10B)	0.9700
O(1)-C(1)	1.417(3)	C(11)-H(11A)	0.9700
O(2)-C(12)	1.254(3)	C(11)-H(11B)	0.9700
S(1)-C(8)	1.755(2)	C(12)-C(13)	1.509(3)

S(1)-C(5)	1.778(2)	C(13)-C(14)	1.379(3)
C(1)-H(1A)	0.9600	C(13)-C(18)	1.386(3)
C(1)-H(1B)	0.9600	C(14)-C(15)	1.380(3)
C(1)-H(1C)	0.9600	C(14)-H(14)	0.9300
C(2)-C(7)	1.381(3)	C(15)-C(16)	1.366(3)
C(2)-C(3)	1.387(3)	C(15)-H(15)	0.9300
C(3)-C(4)	1.383(3)	C(16)-C(17)	1.379(4)
C(3)-H(3)	0.9300	C(16)-H(16)	0.9300
C(4)-C(5)	1.384(3)	C(17)-C(18)	1.381(3)
C(4)-H(4)	0.9300	C(17)-H(17)	0.9300
C(5)-C(6)	1.393(3)	C(18)-H(18)	0.9300
C(6)-C(7)	1.368(3)		

Bond angles (°)

C(9)-N(1)-C(11)	111.79(19)	N(2)-C(9)-C(8)	126.3(2)
C(9)-N(1)-H(1)	124.1	N(1)-C(9)-C(8)	124.6(2)
C(11)-N(1)-H(1)	124.1	N(2)-C(10)-C(11)	103.20(19)
C(9)-N(2)-C(10)	111.6(2)	N(2)-C(10)-H(10A)	111.1
C(9)-N(2)-H(2)	124.2	C(11)-C(10)-H(10A)	111.1
C(10)-N(2)-H(2)	124.2	N(2)-C(10)-H(10B)	111.1
C(2)-O(1)-C(1)	117.4(2)	C(11)-C(10)-H(10B)	111.1
C(8)-S(1)-C(5)	104.70(10)	H(10A)-C(10)-H(10B)	109.1
O(1)-C(1)-H(1A)	109.5	N(1)-C(11)-C(10)	102.5(2)
O(1)-C(1)-H(1B)	109.5	N(1)-C(11)-H(11A)	111.3
H(1A)-C(1)-H(1B)	109.5	C(10)-C(11)-H(11A)	111.3
O(1)-C(1)-H(1C)	109.5	N(1)-C(11)-H(11B)	111.3
H(1A)-C(1)-H(1C)	109.5	C(10)-C(11)-H(11B)	111.3
H(1B)-C(1)-H(1C)	109.5	H(11A)-C(11)-H(11B)	109.2
O(1)-C(2)-C(7)	115.6(2)	O(2)-C(12)-C(8)	123.6(2)
O(1)-C(2)-C(3)	124.8(2)	O(2)-C(12)-C(13)	117.0(2)
C(7)-C(2)-C(3)	119.5(2)	C(8)-C(12)-C(13)	119.33(19)
C(4)-C(3)-C(2)	119.5(2)	C(14)-C(13)-C(18)	118.1(2)
C(4)-C(3)-H(3)	120.3	C(14)-C(13)-C(12)	120.0(2)
C(2)-C(3)-H(3)	120.3	C(18)-C(13)-C(12)	121.9(2)
C(3)-C(4)-C(5)	121.5(2)	C(13)-C(14)-C(15)	121.3(2)
C(3)-C(4)-H(4)	119.2	C(13)-C(14)-H(14)	119.3
C(5)-C(4)-H(4)	119.2	C(15)-C(14)-H(14)	119.3
C(4)-C(5)-C(6)	117.9(2)	C(16)-C(15)-C(14)	120.0(2)
C(4)-C(5)-S(1)	118.36(17)	C(16)-C(15)-H(15)	120.0
C(6)-C(5)-S(1)	123.73(17)	C(14)-C(15)-H(15)	120.0

C(7)-C(6)-C(5)	121.1(2)	C(15)-C(16)-C(17)	119.8(2)
C(7)-C(6)-H(6)	119.5	C(15)-C(16)-H(16)	120.1
C(5)-C(6)-H(6)	119.5	C(17)-C(16)-H(16)	120.1
C(6)-C(7)-C(2)	120.5(2)	C(16)-C(17)-C(18)	120.1(2)
C(6)-C(7)-H(7)	119.7	C(16)-C(17)-H(17)	120.0
C(2)-C(7)-H(7)	119.7	C(18)-C(17)-H(17)	120.0
C(12)-C(8)-C(9)	120.69(19)	C(17)-C(18)-C(13)	120.7(2)
C(12)-C(8)-S(1)	121.79(16)	C(17)-C(18)-H(18)	119.6
C(9)-C(8)-S(1)	117.33(17)	C(13)-C(18)-H(18)	119.6
N(2)-C(9)-N(1)	109.1(2)		

Torsion angles (°)

C(1)-O(1)-C(2)-C(7)	174.9(2)	C(12)-C(8)-C(9)-N(1)	-179.3(2)
C(1)-O(1)-C(2)-C(3)	-5.1(3)	S(1)-C(8)-C(9)-N(1)	5.6(3)
O(1)-C(2)-C(3)-C(4)	179.1(2)	C(9)-N(2)-C(10)-C(11)	-9.7(3)
C(7)-C(2)-C(3)-C(4)	-0.9(3)	C(9)-N(1)-C(11)-C(10)	-12.1(3)
C(2)-C(3)-C(4)-C(5)	-0.3(3)	N(2)-C(10)-C(11)-N(1)	12.3(3)
C(3)-C(4)-C(5)-C(6)	1.4(3)	C(9)-C(8)-C(12)-O(2)	-3.7(3)
C(3)-C(4)-C(5)-S(1)	-178.29(17)	S(1)-C(8)-C(12)-O(2)	171.19(18)
C(8)-S(1)-C(5)-C(4)	169.52(17)	C(9)-C(8)-C(12)-C(13)	177.3(2)
C(8)-S(1)-C(5)-C(6)	-10.1(2)	S(1)-C(8)-C(12)-C(13)	-7.8(3)
C(4)-C(5)-C(6)-C(7)	-1.3(3)	O(2)-C(12)-C(13)-C(14)	-64.5(3)
S(1)-C(5)-C(6)-C(7)	178.36(17)	C(8)-C(12)-C(13)-C(14)	114.5(2)
C(5)-C(6)-C(7)-C(2)	0.1(4)	O(2)-C(12)-C(13)-C(18)	113.4(3)
O(1)-C(2)-C(7)-C(6)	-179.0(2)	C(8)-C(12)-C(13)-C(18)	-67.6(3)
C(3)-C(2)-C(7)-C(6)	1.0(4)	C(18)-C(13)-C(14)-C(15)	0.5(4)
C(5)-S(1)-C(8)-C(12)	107.30(19)	C(12)-C(13)-C(14)-C(15)	178.5(2)
C(5)-S(1)-C(8)-C(9)	-77.62(18)	C(13)-C(14)-C(15)-C(16)	-0.6(4)
C(10)-N(2)-C(9)-N(1)	2.4(3)	C(14)-C(15)-C(16)-C(17)	-0.2(4)
C(10)-N(2)-C(9)-C(8)	-176.5(2)	C(15)-C(16)-C(17)-C(18)	1.1(4)
C(11)-N(1)-C(9)-N(2)	6.5(3)	C(16)-C(17)-C(18)-C(13)	-1.2(4)
C(11)-N(1)-C(9)-C(8)	-174.6(2)	C(14)-C(13)-C(18)-C(17)	0.4(4)
C(12)-C(8)-C(9)-N(2)	-0.5(3)	C(12)-C(13)-C(18)-C(17)	-177.6(2)
S(1)-C(8)-C(9)-N(2)	-175.64(18)		

Spectra of Target Compounds 3–5




Figure S1 ^1H NMR spectrum (500 MHz, CDCl_3) of compound 3a




Figure S2 ¹³C NMR spectrum (125 MHz, CDCl₃) of compound 3a




Figure S3 ^1H NMR spectrum (500 MHz, CDCl_3) of compound **3b**




Figure S4 ¹³C NMR spectrum (125 MHz, CDCl₃) of compound **3b**




Figure S5 ¹H NMR spectrum (500 MHz, CDCl₃) of compound **3c**




Figure S6 ¹³C NMR spectrum (125 MHz, CDCl₃) of compound 3c




Figure S7 ¹H NMR spectrum (500 MHz, CDCl₃) of compound **3d**




Figure S8 ^{13}C NMR spectrum (125 MHz, CDCl_3) of compound **3d**




Figure S9 ¹H NMR spectrum (500 MHz, CDCl₃) of compound **3e**

DEPT135




Figure S10 ¹³C NMR spectrum (125 MHz, CDCl₃) of compound **3e**




Figure S11 ^1H NMR spectrum (500 MHz, CDCl_3) of compound **3f**




Figure S12 ^{13}C NMR spectrum (125 MHz, CDCl_3) of compound **3f**




Figure S13 ¹H NMR spectrum (500 MHz, CDCl₃) of compound **3g**




Figure S14 ^{13}C NMR spectrum (125 MHz, CDCl_3) of compound **3g**




Figure S15 ¹H NMR spectrum (500 MHz, CDCl₃) of compound **3h**




Figure S16 ^{13}C NMR spectrum (125 MHz, CDCl_3) of compound **3h**




Figure S17 ^1H NMR spectrum (500 MHz, CDCl_3) of compound **3i**




Figure S18 ¹³C NMR spectrum (125 MHz, CDCl₃) of compound 3i




Figure S19 ^1H NMR spectrum (500 MHz, CDCl_3) of compound **3j**




Figure S20 ^{13}C NMR spectrum (125 MHz, CDCl_3) of compound **3j**




Figure S21 ^1H NMR spectrum (500 MHz, CDCl_3) of compound **3k**




Figure S22 ^{13}C NMR spectrum (125 MHz, CDCl_3) of compound **3k**




Figure S23 ¹H NMR spectrum (500 MHz, CDCl₃) of compound **3l**




Figure S24 ¹³C NMR spectrum (125 MHz, CDCl₃) of compound 3l




Figure S25 ¹H NMR spectrum (500 MHz, CDCl₃) of compound **3m**




Figure S26 ^{13}C NMR spectrum (125 MHz, CDCl_3) of compound **3m**




Figure S27 ¹H NMR spectrum (500 MHz, CDCl₃) of compound **3n**




Figure S28 ¹³C NMR spectrum (125 MHz, DMSO-*d*₆) of compound 3n




Figure S29 ^1H NMR spectrum (500 MHz, CDCl_3) of compound **3o**




Figure S30 ^{13}C NMR spectrum (125 MHz, CDCl_3) of compound **3o**




Figure S31 ^1H NMR spectrum (500 MHz, CDCl_3) of compound 3p




Figure S32 ¹³C NMR spectrum (125 MHz, CDCl₃) of compound 3p




Figure S33 ^1H NMR spectrum (500 MHz, CDCl_3) of compound **3q**




Figure S34 ¹³C NMR spectrum (125 MHz, CDCl₃) of compound 3q




Figure S35 ^1H NMR spectrum (500 MHz, $\text{DMSO}-d_6$) of compound **4a**




Figure S36 ^{13}C NMR spectrum (125 MHz, CDCl_3) of compound 4a




Figure S37 ¹H NMR spectrum (500 MHz, CDCl₃) of compound **4b**





Figure S38 ^{13}C NMR spectrum (125 MHz, CDCl_3) of compound **4b**






Figure S40 ^{13}C NMR spectrum (125 MHz, CDCl_3) of compound **4c**




Figure S41 ¹H NMR spectrum (400 MHz,) of compound **4d**




Figure S42 ^{13}C NMR spectrum (100 MHz,) of compound **4d**




Figure S43 ^1H NMR spectrum (500 MHz, CDCl_3) of compound **4e**




Figure S44 ^{13}C NMR spectrum (125 MHz, CDCl_3) of compound **4e**




Figure S45 ^1H NMR spectrum (400 MHz, CDCl_3) of compound **4f**




Figure S46 ^{13}C NMR spectrum (100MHz, CDCl_3) of compound **4f**




Figure S47 ^1H NMR spectrum (400 MHz, CDCl_3) of compound **4g**




Figure S48 ^{13}C NMR spectrum (100 MHz, CDCl_3) of compound **4g**




Figure S49 ^1H NMR spectrum (500 MHz, CDCl_3) of compound **4h**





Figure S50 ^{13}C NMR spectrum (125 MHz, CDCl_3) of compound **4h**






Figure S52. ¹³C NMR (125 MHz, CDCl₃) spectra of compound **4i**




Figure S53. ¹H NMR (500 MHz, CDCl₃) spectra of compound **4j**






Figure S54. ^{13}C NMR (125 MHz, CDCl_3) spectra of compound **4j**








Figure S57. ^1H NMR (500 MHz, CDCl_3) spectra of compound **4l**




Figure S58. ^{13}C NMR (125 MHz, CDCl_3) spectra of compound **4l**




Figure S59. ^1H NMR (500 MHz, CDCl_3) spectra of compound **4m**




Figure S60. ^{13}C NMR (125 MHz, CDCl_3) spectra of compound **4m**




Figure S61. ^1H NMR (500 MHz, CDCl_3) spectra of compound **4n**




Figure S62. ^{13}C NMR (125 MHz, CDCl_3) spectra of compound **4n**




Figure S63. ^1H NMR (500 MHz, CDCl_3) spectra of compound **4o**




Figure S64. ^{13}C NMR (125 MHz, CDCl_3) spectra of compound **4o**




Figure S65. ^1H NMR (500 MHz, CDCl_3) spectra of compound **4p**




Figure S66. ¹³C NMR (125 MHz, CDCl₃) spectra of compound 4p

YUNNAN UNIVER. AV. DRX500
jiangxiuyang JXY-A-8 in CDCl_3
13050901




Figure S67. ^1H NMR (500 MHz, CDCl_3) spectra of compound 4q




Figure S68. ^{13}C NMR (125 MHz, CDCl_3) spectra of compound **4q**




Figure S69. ^1H NMR (500 MHz, CDCl_3) spectra of compound **4r**




Figure S70. ¹³C NMR (125 MHz, CDCl₃) spectra of compound 4r




Figure S71. ^1H NMR (500 MHz, CDCl_3) spectra of compound 5a




Figure S72. ^{13}C NMR (125 MHz, CDCl_3) spectra of compound **5a**




Figure S73. ^1H NMR (500 MHz, CDCl_3) spectra of compound **5b**




Figure S74. ¹³C NMR (125 MHz, CDCl₃) spectra of compound 5b




Figure S75. ^1H NMR (500 MHz, CDCl_3) spectra of compound **5c**




Figure S76. ¹³C NMR (125 MHz, CDCl₃) spectra of compound 5c




Figure S77. ^1H NMR (500 MHz, CDCl_3) spectra of compound **5d**




Figure S78. ¹³C NMR (125 MHz, CDCl₃) spectra of compound **5d**




Figure S79. ^1H NMR (500 MHz, CDCl_3) spectra of compound **5e**




Figure S80. ^{13}C NMR (125 MHz, CDCl_3) spectra of compound **5e**





Figure S81. ^1H NMR (500 MHz, CDCl_3) spectra of compound **5f**






Figure S83. ¹H NMR (500 MHz, CDCl₃) spectra of compound **5g**




Figure S84. ^{13}C NMR (125 MHz, CDCl_3) spectra of compound **5g**




Figure S85. ^1H NMR (500 MHz, CDCl_3) spectra of compound **5h**





Figure S86. ^{13}C NMR (125 MHz, CDCl_3) spectra of compound **5h**






Figure S88. ^{13}C NMR (125 MHz, CDCl₃) spectra of compound 5i





Figure S89. ^1H NMR (500 MHz, CDCl_3) spectra of compound **5j**

DEPT90



DEPT135

YUNNAN UNIVER AV. DRX500
jiangxiuyang JXY-21 in CDCl₃
13030503




Figure S90. ¹³C NMR (125 MHz, CDCl₃) spectra of compound **5j**




Figure S91. ^1H NMR (500 MHz, CDCl_3) spectra of compound **5k**




Figure S92. ^{13}C NMR (125 MHz, CDCl_3) spectra of compound **5k**




Figure S93. ^1H NMR (500 MHz, CDCl_3) spectra of compound **5l**




Figure S94. ^{13}C NMR (125 MHz, CDCl₃) spectra of compound **5l**




Figure S95. ^1H NMR (500 MHz, CDCl_3) spectra of compound **5m**




Figure S96. ^{13}C NMR (125 MHz, CDCl_3) spectra of compound **5m**

Notes and References

1. (a) Huang, Z.-T.; Wang, M.-X. *Synthesis* **1992**, *12*, 1273–1276. (b) Li, Z.-J.; Charles, D. *Synth. Commun.* **2001**, *31*, 527–533. (c) X.-B. Chen, X.-M. Liu, R. Huang, S.-J. Yan, J. Lin, *Eur. J. Org. Chem.* **2013**, 4607.
2. CCDC 949284 which containing in the electronic supplementary information (ESI) for crystallographic data of compound **3g**. This material is available free of charge from The Cambridge Crystallographic Data Center *via* the Internet at www.ccdc.cam.ac.uk/data_request/cif.